阿尔茨海默病是一种疾病吗?
Amos D Korczyn1, Lea T Grinberg2,3,4
1Departments of Neurology, Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel. Amoskor@tauex.tau.ac.il.
Nature reviews. Neurology
|February 29, 2024
概括
尽管进行了广泛的研究,阿尔茨海默病 (AD) 仍然没有治愈方法. 目前针对粉样β斑块和团的方法不足,需要对这种复杂综合征采取多方面的策略.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 病理学 病理学 病理学
背景情况:
- 痴呆症,特别是阿尔茨海默病 (AD),对老年人口产生重大影响.
- 阿尔茨海默病的特点是粉样β斑块和团,但它们的直接毒性和形成机制尚不清楚.
- 目前针对粉样β的治疗方法没有阻止神经退行,这质疑了现有的治疗范式.
研究的目的:
- 批判性地评估了解和治疗阿尔茨海默病的进展.
- 探索阿尔茨海默病的复杂性质,作为一种由病原性途径融合而产生的综合征.
- 倡导转向多方面的治疗策略来治疗AD.
主要方法:
- 审查有关阿尔茨海默病病因的现有研究,包括粉样β和.
- 分析当前诊断和治疗方法的局限性.
- 综合证据支持AD作为一个复杂的综合征与多种不同的贡献因素.
主要成果:
- 缺乏关于粉样β毒性的确证据.
- 斑块和结积累的机制尚未完全理解.
- 粉样蛋白-β的去除尚未被证明有效地阻止神经退行.
结论:
- 阿尔茨海默病是一种复杂的综合征,而不是单一的疾病,有多种导致因素.
- 单一的"银子弹"方法对于治疗AD是不够的.
- 需要同时应用多种策略来改善AD的识别,分类和治疗.
相关概念视频
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Amnesia
126
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
126
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


